Related Experiment Videos

Impotence in patients treated with clofibrate

Atherosclerosis
|May 1, 1975
PubMed

Insights

Clofibrate treatment for hyperlipoproteinemia may cause impotence in some patients. Symptoms improved after stopping the drug, but recurred upon re-administration in one case.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Type IV hyperlipoproteinemia is a lipid disorder requiring management.
  • Clofibrate is a medication used to treat hyperlipoproteinemia.
  • Cardiovascular risk factors, including hyperlipidemia and prior myocardial infarction, are significant.

Purpose of the Study:

  • To investigate the potential link between clofibrate therapy and impotence.
  • To assess the reversibility of impotence after clofibrate discontinuation.

Main Methods:

  • Observational case series involving three patients with Type IV hyperlipoproteinemia.
  • Monitoring of sexual function in patients undergoing clofibrate treatment.
  • Interruption and re-initiation of clofibrate therapy to evaluate symptom changes.

Main Results:

  • Three patients developed impotence within one year of starting clofibrate.
  • Two patients experienced symptom improvement within 3-4 weeks of drug cessation.
  • Impotence recurred in one patient upon resuming clofibrate therapy.

Conclusions:

  • Clofibrate may be associated with the development of impotence in patients with Type IV hyperlipoproteinemia.
  • The observed impotence appears to be reversible upon discontinuation of clofibrate.
  • Further investigation into the mechanism and prevalence of this side effect is warranted.

Related Concept Videos